NeuroNova has established proprietary platform technologies, which are assembled into a comprehensive discovery process designed to support the identification of therapeutically relevant drug targets and compounds.

The Neurogenesis Qualifier combines in-house expertise in in vitro and in vivo methods with state-of-the-art drug discovery technologies. It is broadly applicable to several CNS therapeutic areas, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

The technology platform’s focus is on data quality and content in order to facilitate scientific decision-making throughout the drug discovery process. The Neurogenesis Qualifier is supported by proprietary in-house databases and tools to efficiently manage volumes of research data, making critical information readily available to our scientists.

The Neurogenesis Qualifier can be used  to investigate the medicinal potential of novel drug targets and compounds and to identify new CNS uses for existing drugs, thereby providing diversity and balanced risk.

NeuroNova’s unique discovery process has already generated a robust pipeline of validated drug targets and drug candidates that demonstrate potential in the treatment of neurodegenerative diseases.